文献速递神经肿瘤

转谷氨酰胺酶2抑制增强替莫唑胺对胶质母细胞瘤球疗效

Pharmacological transglutaminase 2 inhibition enhances temozolomide response in patient-derived glioblastoma tumorspheres.
PubMed 文献 · J Neurooncol · 2026-01-03

本研究评估TGM2抑制剂链黑霉素(SN)联合替莫唑胺(TMZ)对两株患者来源胶质母细胞瘤球(TS15-88、TS19-156)的疗效。联合治疗较单药显著降低细胞活力和ATP、诱导凋亡、减少干性与侵袭,并在小鼠原位异种移植模型中延长生存、降低侵袭相关蛋白表达。

要点

  • SN联合TMZ较单药更强抑制GBM肿瘤球增殖并诱导凋亡。
  • 联合治疗降低GBM肿瘤球干性与侵袭性及相关蛋白/mRNA表达。
  • 小鼠原位模型中联合治疗延长生存并降低侵袭相关蛋白表达。

核心结论

  • 靶向TGM2的SN可增强TMZ在GBM中的疗效,联合方案值得进一步机制与转化研究。

研究设计与样本

  • 研究采用两株患者来源GBM肿瘤球(TS15-88为proneural亚型,TS19-156为classical亚型),分别给予SN、TMZ或联合处理。
  • 体外检测细胞活力与ATP,Bliss协同评分量化协同,流式细胞术分析凋亡,神经球形成与三维侵袭实验评估干性与侵袭。
  • 蛋白与mRNA分别用western blotting与RNA测序评估,体内疗效用小鼠原位异种移植模型评价。

主要发现

  • SN与TMZ联合较任一单药显著降低细胞活力和ATP水平,并更有效诱导凋亡。
  • 联合治疗有效降低GBM肿瘤球的干性与侵袭性,并降低相关蛋白和mRNA表达。
  • 体内联合治疗延长小鼠生存,免疫组化显示侵袭相关蛋白表达降低。

临床怎么用

  • 结果提示TGM2抑制联合TMZ可能作为GBM的潜在治疗策略,但尚需进一步机制与转化研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor, with a median survival of less than two years despite standard therapy. Transglutaminase 2 (TGM2) contributes to tumor progression and poor clinical outcomes. This study evaluated the therapeutic potential of combining streptonigrin (SN), a TGM2 inhibitor, with temozolomide (TMZ), the standard chemotherapeutic agent for GBM. METHODS: Two patient-derived GBM tumorspheres (TSs; TS15-88, proneural subtype; TS19-156, classical subtype) were treated with SN, TMZ, or their combination. Cell viability and ATP production were measured to assess cell proliferation, and synergy was quantified using the Bliss synergy score. Apoptosis was analyzed by flow cytometry. Stemness and invasiveness were evaluated using neurosphere formation and three-dimensional invasion assays. Protein and mRNA expression levels were assessed by western blotting and RNA sequencing. In vivo efficacy was evaluated using a mouse orthotopic xenograft model. RESULTS: The combination of SN and TMZ significantly reduced cell viability and ATP levels and induced apoptosis more effectively than either agent alone. Moreover, combination treatment effectively reduced stemness and invasiveness in GBM TSs, along with the expression of related proteins and mRNAs. In vivo, combination therapy prolonged survival in mice and reduced the expression of invasion-related proteins, as demonstrated by immunohistochemistry. CONCLUSION: These findings suggest that targeting TGM2 with SN enhances the therapeutic efficacy of TMZ in GBM. The combination of SN and TMZ may represent one potential therapeutic approach for GBM and warrants further mechanistic and translational investigation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hong JP, Hong JB, Lee B, et al. Pharmacological transglutaminase 2 inhibition enhances temozolomide response in patient-derived glioblastoma tumorspheres. J Neurooncol. 2026. PMID: 41483361. doi:10.1007/s11060-025-05412-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。